Abstract
Osteoarthritis is the most common form of arthritis and unfortunately lacks disease-modifying treatments. This has led to a growing demand for more effective nonoperative treatment options. Platelet-rich plasma and mesenchymal stem cell therapy offer the potential to modify the natural course of knee osteoarthritis using cell-based technology. Because of the lack of high-quality evidence and the large degree of heterogeneity, in terms of study designs and measured outcomes, the use of platelet-rich plasma or mesenchymal stem cell therapy to treat knee osteoarthritis cannot be recommended at this time.
Original language | English (US) |
---|---|
Pages (from-to) | 417-438 |
Number of pages | 22 |
Journal | Rheumatic Disease Clinics of North America |
Volume | 45 |
Issue number | 3 |
DOIs | |
State | Published - Aug 2019 |
Keywords
- Knee osteoarthritis
- Meta-analyses
- Osteoarthritis
- Platelet-rich plasma
- Randomized controlled clinical trials
- Regenerative medicine
- Stem cells
ASJC Scopus subject areas
- Rheumatology